Golden Helix Enters the Clinical Testing Market with VarSeq

Bozeman, MT (September 30, 2014) — Today, Golden Helix, Inc. announced the release of VarSeq and their entry into the clinical testing market. VarSeq is a new software tool that supports both gene panel based diagnostics as well as the application of clinical workflows based on Next-Gen sequencing data.

"Our part here at Golden Helix is to essentially build the equivalent of an MRI for the genome", said Andreas Scherer, president and CEO of Golden Helix. "For over 15 years, Golden Helix has provided tools for the research community to better understand the underlying mechanisms of disease. Now, we will do the same for clinicians, genetic counselors, and any other medical specialist in need of the best possible tool to consistently create reliable, clinical diagnosis."

VarSeq software streamlines the process of annotating and filtering variants obtained from next generation sequencing pipelines, allowing both research scientists and clinicians to find variants of interest in a very efficient and straightforward manner. VarSeq simplifies the user interface and provides a scalable architecture featuring repeatable workflows, note taking and reporting, and filter parameter prototyping.

VarSeq will be unveiled during a webcast tomorrow, Wednesday, October 1st at noon EDT – Introducing VarSeq: Variant Discovery & Gene Panels Made Easy. To register, and for more information on VarSeq, please visit the Golden Helix website at

About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over 15 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from micro-arrays and DNA sequencing. With our solutions, hundreds of the world's top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 800 peer-reviewed publications.

Cheryl Rogers
Director of Marketing
Golden Helix, Inc.